DCCT (Diabetes Control and Complications Trial)

Before the DCCT, the link between blood glucose control and diabetic complications was contested. Observational data supported it, and animal models were consistent, but no large randomized trial had directly tested whether achieving near-normal glycemia in type 1 diabetes would prevent retinopathy, neuropathy, or nephropathy. Some endocrinologists remained skeptical; others worried that aggressive insulin therapy simply caused dangerous hypoglycemia without meaningful clinical gain. The question had practical stakes for every patient with type 1 diabetes.

Planned from 1982 under Oscar Crofford, the Diabetes Control and Complications Trial began with 21 centers, added 8 more after a two-year feasibility phase, and finished recruiting its 1,441 patients, 726 without retinopathy and 715 with mild retinopathy, in early 1989. Half were randomized to intensive therapy, with an insulin pump or three or more daily injections guided by frequent glucose monitoring, and half to conventional therapy with one or two daily injections. Participants were followed for a mean of 6.5 years, and the trial was completed in 1993.

Intensive therapy cut the risk of retinopathy by 76% in patients without preexisting retinopathy, and slowed progression by 54% in those who already had early changes. Clinical neuropathy fell by 60%, microalbuminuria, the earliest marker of diabetic kidney disease, by 39%, and albuminuria by 54%. HbA1c averaged about 7% with intensive therapy against about 9% with conventional therapy. An HbA1c below 7% was then adopted worldwide as the treatment target for type 1 diabetes.

The cost was concrete: patients in the intensive arm experienced two to three times the rate of severe hypoglycemia requiring assistance. This finding shaped how physicians applied the DCCT results. Tight control became the target, but it was modulated by individual risk for hypoglycemia, which varied with age, awareness status, comorbidities, and social circumstances. The results defined a target and a hazard at the same time.

Follow-up through the Epidemiology of Diabetes Interventions and Complications study, EDIC, which began in 1994, found that the benefits persisted for about 10 years after HbA1c levels in the two groups converged, an effect its investigators called metabolic memory. Intensive therapy during the DCCT years also reduced cardiovascular events in the long-term EDIC follow-up. Prior intensive therapy was later linked to lower mortality as well, and 96 percent of the original cohort joined EDIC.